TheraVasc is developing a repurposed drug, TV1001, an oral formulation of sodium nitrite, to target patient populations with poor blood flow to the extremities, such as those with diabetic leg and foot problems or those with peripheral artery disease (PAD). While there is a large and growing number of patients suffering from such health problems, there is no effective treatment available. TV1001 has been shown to selectively promote the re-growth of blood vessels in ischemic tissues such as those affected in patients with diabetes or PAD. TheraVasc has received investment from the North Coast Angel Fund, Jumpstart Evergreen, Focus, and Next Funds, and GLIDE.
Stanton Advanced Ceramics, Inc developed FireSlayer, a patented, reinforced advanced ceramic technology (“RACT”) with the goal of becoming a new standard in refractory linings for furnaces. The material can withstand heat significantly better than current furnace lining material. Stanton´s FireSlayer offers furnaces resistance to: corrosion, thermal shock, and high temperatures, as well as provids superior thermal insulation. The result is decreased furnace downtime, substantially increased revenues (due to lower downtimes), meaningful savings to labor costs, and lower energy costs. Stanton Advanced Ceramics has received investment from the North Coast Angel Fund and Jumpstart.
SparkBase is a stored-value and gift card transaction processor located in Cleveland. It provides private-label, stored-value, specialty gift cards, customer loyalty, and community rewards programs to Independent Sales Organizations (independent companies used by banks to develop new merchant relationships on their behalf). ISOs may then sell these gift and loyalty products to merchant customers, along with credit card services and processing equipment. SparkBase has received investment from the North Coast Angel Fund and Jumpstart.
SironRX Therapeutics was developing novel therapies to promote dermal wound repair and reduce scarring. The company’s therapeutic platform was based on the delivery of Stromal cell-Derived Factor 1 (SDF-1), which has been shown to promote tissue repair by recruiting stem cells to the damaged organ. SDF-1 has also been shown to prevent cell death and promote new blood vessel formation. SironRx Therapeutics has received investment from the North Coast Angel Fund, Cleveland Clinic, and Jumpstart Next, Evergreen, and Focus Funds.
OnShift is a leading provider of integrated employee scheduling and communications technology with an aim to optimize labor utilization and control labor costs for employers with shift-based workforces. OnShift’s flagship product is an intuitive, web-based application that combines staff scheduling, work requirements, employee qualifications, business rules, and communications into a highly automated staff management system. Their focus is the senior-living industry, providing OnShift with a breadth of knowledge and understanding of this area, specifically on how providers work day-in and day-out and on the effects of industry regulations and issues. OnShift has received investment from the North Coast Angel Fund and the Jumpstart Evergreen, Focus, Next Funds, and Flashline Partners.
Nine Iron Innovations provided an automated mobile video monitoring system for golf course contests and events. The company’s product portfolio included VerishotMobile, a golf shot video monitoring, contest, and marketing program for golf courses, event managers, golf management organizations, and independent representatives. It also included Sharegolf.com, a social networking site that connected golf courses and golfers, and allowed them to view and share videos of their swings with other members. Nine Iron Innovations has received investment from the North Coast Angel Fund and the Jumpstart Fund.
Neuros Medical, a Cleveland-based neurostimulation company, is focused on developing neurostimulation therapies for unmet needs to patients worldwide. The company’s platform technology, Electrical Nerve Block, works to eliminate chronic pain and spasticity in a variety of applications, including neuroma/residual limb pain, chronic post surgical pain, and chronic migraine. Neuros has received investment from the North Coast Angel Fund and the Jumpstart Evergreen, Focus, and Next Funds.
Great Lakes Pharmaceuticals, Inc. is a clinical stage company focused on developing and commercializing products that prevent infections associated with indwelling catheters. Their first product, B-Lock™, is an anticoagulant catheter lock solution that works against the bacterial and fungal microorganisms known to form biofilm structures in catheters. Biofilm-related infections are the 8th leading cause of death in the United States. Headquartered in Concord, OH with offices in San Diego, CA, Great Lakes Pharmaceuticals assembled teams of experienced and distinguished scientists, clinicians, and managers to assure a smooth development as well as the commercialization of innovative, effective treatments of microbial infections in clinical and outpatient settings. Great Lakes Pharmaceuticals has received investment from the North Coast Angel Fund and the Jumpstart Evergreen, Next, and Focus funds.
GenomOncology is in the personalized medicine space with a proprietary technology platform to rapidly analyze sequenced genomic data for use in cancer treatment. The platform enables users to browse, filter, and map variations at many different levels to discover the genetic mutations that are unique to the tumor. From this analysis, the company generates a customizable report, including findings and clinical recommendations based on the observed actionable mutations in the tumor genome. Considering cancer is a disease of genetic mutation, this type of personalized approach represents the future of oncology. GenomOncology has received investment from the North Coast Angel Fund and the Jumpstart Evergreen, Next, and Focus funds.
Cryothermic Systems (formerly known as LifeCore Technologies) offers the Excel ® Cryo Cooling System for immediate and selective cooling of the brain after cardiac arrest, stroke, or traumatic brain injury. A 2009 Cath Lab Digest study reported that, “for every hour to first cooling, the relative hazard of death increases 29%.” The coolant and collar system was recently honored for its innovative design and ease of use by EMS Pro Magazine and by the Journal of Emergency Medical Services. The company is working to accelerate adoption by hospitals and EMS services. Cryothermic Systems has received funding from the North Coast Angel Fund and the Jumpstart Next, Evergreen, and Focus Funds.